EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Treatment‐Free Remission Outcomes in a BCR :: ABL1 Digital PCR Selected Clinical Cohort of CML Patients

C Kockerols iD, P J M Valk, P Hogenbirk, I Geelen iD, N M A Blijlevens, J J W M Janssen, M Hoogendoorn, S Kersting, S K Klein, L G M Daenen, M Donker, P A W Te Boekhorst und 17 weitere

European Journal of Haematology · 2025

DOI: 10.1111/ejh.14368 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von C Kockerols und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands. Hauptthemen laut MEDLINE: Fusion Proteins, bcr-abl, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Polymerase Chain Reaction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Approximately 40%–60% of patients reaching a stable deep molecular response during TKI treatment will maintain a state of remission after TKI discontinuation, denoted as treatment‐free remission (TFR). Depth of molecular response assessed by BCR::ABL1 digital PCR prior to TKI discontinuation has demonstrated its significance as a reliable predictive parameter for TFR. A clinically applicable prediction cutoff of 0.0023%IS has been established and externally validated. In this study, BCR::ABL1 digital PCR, as most sensitive and stable assay of its kind, was investigated as a TFR prediction tool in the Netherlands, and evaluated for its predictive value to stop TKI treatment below the aforementioned cutoff. The primary endpoint of molecular recurrence (MolR, BCR::ABL1 > 0.1%IS) at 12 months was prospectively assessed. Overall, 67 discontinued patients below the set BCR::ABL1 digital PCR cutoff were included. The overall MolR probability was 50% (95% CI, 36%–62%). In 38 patients treated for more than 6 years as commonly recommended as desirable treatment duration before TFR attempt, the MolR probability dropped to 36% (95% CI, 18%–50%). Patients attempting an early TKI discontinuation (treated for less than 6 years) had a high MolR probability of 76% (95% CI, 65%–89%). BCR::ABL1 digital PCR was successfully used in Dutch clinical practice. Our study indicates that in patients with a low BCR::ABL1 digital PCR result, a total TKI treatment duration of six or more years remains associated with a lower MolR rate and should generally be pursued. In patients treated for more than 6 years, BCR::ABL1 digital PCR was capable to identify stop candidates with a higher probability of TFR success.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fusion Proteins, bcr-ablLeukemia, Myelogenous, Chronic, BCR-ABL PositivePolymerase Chain ReactionHumansMaleFemaleMiddle AgedAdultRemission InductionAgedProtein Kinase InhibitorsTreatment OutcomeYoung Adult

Stichwörter der Autor:innen

BCR::ABL1 digital PCRchronic myeloid leukemiatreatment‐free remissiontyrosine kinase inhibitor treatment discontinuation

Substanzen

Fusion Proteins, bcr-ablProtein Kinase InhibitorsBCR-ABL1 fusion protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
  • Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Internal Medicine, Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands.
  • Department of Hematology, Haga Ziekenhuis, The Netherlands.
  • Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.

ORCID-Profile: C Kockerols, I Geelen, P E Westerweel

Förderung

  • ZonMw

Zitieren

APA

Kockerols, C., Valk, P. J. M., Hogenbirk, P., Geelen, I., Blijlevens, N. M. A., Janssen, J. J. W. M., Hoogendoorn, M., Kersting, S., Klein, S. K., Daenen, L. G. M., Donker, M., Te Boekhorst, P. A. W., Jie, K. G., Corsten, M., Cruijsen, M. J., Levenga, H., Smit, W. M., Levin, M. D., de Jongh, E., …, & Collaborating Authors (2025). Treatment‐Free Remission Outcomes in a BCR :: ABL1 Digital PCR Selected Clinical Cohort of CML Patients. European Journal of Haematology. https://doi.org/10.1111/ejh.14368

Vancouver

Kockerols C, Valk PJM, Hogenbirk P, Geelen I, Blijlevens NMA, Janssen JJWM, et al. Treatment‐Free Remission Outcomes in a BCR :: ABL1 Digital PCR Selected Clinical Cohort of CML Patients. European Journal of Haematology. 2025. doi:10.1111/ejh.14368

BibTeX
@article{Kockerols2025,
  author = {Kockerols, C and Valk, P J M and Hogenbirk, P and Geelen, I and Blijlevens, N M A and Janssen, J J W M and Hoogendoorn, M and Kersting, S and Klein, S K and Daenen, L G M and Donker, M and Te Boekhorst, P A W and Jie, K-S G and Corsten, M and Cruijsen, M J and Levenga, H and Smit, W M and Levin, M-D and de Jongh, E and de Jonge, S and Vlot, A J and Durian, M F and Zwaginga, J J and Mohlmann, M and Wustman, T J and Blommers, R and Cornelissen, J J and Westerweel, P E and Collaborating Authors, Collaborating Authors},
  title = {Treatment‐Free Remission Outcomes in a BCR :: ABL1 Digital PCR Selected Clinical Cohort of CML Patients},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.14368}
}
Kostenlos starten →